Your browser doesn't support javascript.
loading
The QChip1 knowledgebase and microarray for precision medicine in Qatar.
Rodriguez-Flores, Juan L; Messai-Badji, Radja; Robay, Amal; Temanni, Ramzi; Syed, Najeeb; Markovic, Monika; Al-Khayat, Eiman; Qafoud, Fatima; Nawaz, Zafar; Badii, Ramin; Al-Sarraj, Yasser; Mbarek, Hamdi; Al-Muftah, Wadha; Alvi, Muhammad; Rostami, Mahboubeh R; Cruzado, Juan Carlos Martinez; Mezey, Jason G; Shakaki, Alya Al; Malek, Joel A; Greenblatt, Matthew B; Fakhro, Khalid A; Machaca, Khaled; Al-Nabet, Ajayeb; Afifi, Nahla; Brooks, Andrew; Ismail, Said I; Althani, Asmaa; Crystal, Ronald G.
Afiliação
  • Rodriguez-Flores JL; Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Messai-Badji R; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Robay A; Qatar Genome Program, Qatar Foundation, Doha, Qatar.
  • Temanni R; Weill Cornell Medicine, Doha, Qatar.
  • Syed N; Department of Human Genetics, Sidra Medicine, Doha, Qatar.
  • Markovic M; Department of Human Genetics, Sidra Medicine, Doha, Qatar.
  • Al-Khayat E; Qatar Biobank for Medical Research, Qatar Foundation, Doha, Qatar.
  • Qafoud F; Qatar Biobank for Medical Research, Qatar Foundation, Doha, Qatar.
  • Nawaz Z; Qatar Biobank for Medical Research, Qatar Foundation, Doha, Qatar.
  • Badii R; Diagnostic Genomic Division, Hamad Medical Corporation, Doha, Qatar.
  • Al-Sarraj Y; Weill Cornell Medicine, Doha, Qatar.
  • Mbarek H; Diagnostic Genomic Division, Hamad Medical Corporation, Doha, Qatar.
  • Al-Muftah W; Qatar Genome Program, Qatar Foundation, Doha, Qatar.
  • Alvi M; Qatar Genome Program, Qatar Foundation, Doha, Qatar.
  • Rostami MR; Qatar Genome Program, Qatar Foundation, Doha, Qatar.
  • Cruzado JCM; Qatar Genome Program, Qatar Foundation, Doha, Qatar.
  • Mezey JG; Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Shakaki AA; Department of Biology, University of Puerto Rico at Mayagüez, Mayagüez, Puerto Rico, USA.
  • Malek JA; Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Greenblatt MB; Department of Computational Biology, Cornell University, Ithaca, NY, USA.
  • Fakhro KA; Weill Cornell Medicine, Doha, Qatar.
  • Machaca K; Weill Cornell Medicine, Doha, Qatar.
  • Al-Nabet A; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Afifi N; Weill Cornell Medicine, Doha, Qatar.
  • Brooks A; Department of Human Genetics, Sidra Medicine, Doha, Qatar.
  • Ismail SI; Weill Cornell Medicine, Doha, Qatar.
  • Althani A; Diagnostic Genomic Division, Hamad Medical Corporation, Doha, Qatar.
  • Crystal RG; Qatar Biobank for Medical Research, Qatar Foundation, Doha, Qatar.
NPJ Genom Med ; 7(1): 3, 2022 Jan 19.
Article em En | MEDLINE | ID: mdl-35046417
ABSTRACT
Risk genes for Mendelian (single-gene) disorders (SGDs) are consistent across populations, but pathogenic risk variants that cause SGDs are typically population-private. The goal was to develop "QChip1," an inexpensive genotyping microarray to comprehensively screen newborns, couples, and patients for SGD risk variants in Qatar, a small nation on the Arabian Peninsula with a high degree of consanguinity. Over 108 variants in 8445 Qatari were identified for inclusion in a genotyping array containing 165,695 probes for 83,542 known and potentially pathogenic variants in 3438 SGDs. QChip1 had a concordance with whole-genome sequencing of 99.1%. Testing of QChip1 with 2707 Qatari genomes identified 32,674 risk variants, an average of 134 pathogenic alleles per Qatari genome. The most common pathogenic variants were those causing homocystinuria (1.12% risk allele frequency), and Stargardt disease (2.07%). The majority (85%) of Qatari SGD pathogenic variants were not present in Western populations such as European American, South Asian American, and African American in New York City and European and Afro-Caribbean in Puerto Rico; and only 50% were observed in a broad collection of data across the Greater Middle East including Kuwait, Iran, and United Arab Emirates. This study demonstrates the feasibility of developing accurate screening tools to identify SGD risk variants in understudied populations, and the need for ancestry-specific SGD screening tools.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Genom Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Genom Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos